Board of Directors
Board of Directors
Elisabeth has a MSc in Biochemical Engineering from the Royal Institute of Technology and a MBA from Uppsala University.
She has 30 years+ experience from management within pharmaceutical R&D, as project manager, Head of Department, COO and CEO. Elisabeth has vast international experience from Big Pharma and from smaller companies, both public and non-public. She has recently served as the CEO and COO of OxThera AB. Previous positions include Diamyd Medical AB, OctaPharma AB, Metcon Medicin AB and Pharmacia AB. Previous Board positions include Pharmalink AB, KaroBio AB and Cobra Biologics AB.
Other Appointments
Elisabeth is an independent consultant working from BioSource Europe AB specializing at biopharma Due Diligence work for investors and companies supporting potential acquisitions.
Other Board Appointments
Elisabeth serves a Member of the Scientific Advisory Board for French company 4P Pharma.
Holds no shares in Epicyt Pharma AB
Johan has a Ph.D. in Neurochemistry and Neurotoxicology from Stockholm University and completed post-doctoral training in pharmacology and physiology at the New York University and the University of Oxford, and in business and administration at Warwick University Business School.
Other Appointments
Johan serves as Calliditas Therapeutics’ Chief Scientific Officer since April 2019. Prior to that, he served as SVP Licensing, IP & Legal 2017-2019 at Calliditas Therapeutics AB and as Chief Executive Officer from 2007 to 2017 at Pharmalink AB. He previously served in various managerial and executive roles at Karo Bio AB, Pharmacia Corporation and NeuroNova AB and has in total more than 30 years of experience from drug discovery and development.
Other Board Appointments
Board member of Directors of Nefecon AB.
Holds 6.667 shares in Epicyt Pharma AB.
Sara holds a M.Sc. in Biotechnology and Business Development from the Chalmers University of Technology.
She has 15 years experience working with life science startups and investment analysis of startups within all fields. Today she works with business development of early stage pharmaceutical startups at GU Ventures and in several Board positions.
Other Board Appointments
Board member of Implexion Pharma AB, Endoriz AB and Agmine Pharma AB.
GU Ventures holds 48,809 shares.
Holds 0 shares in pivate in Epicyt Pharma AB.
Anders holds a Bachelor of Economics in business administration from Webster University, Genève.
Anders has been the CEO of several companies within the biotech and the financial sector. For 10 years, Anders held the position as CEO of Isofol Medical AB (publ), developing the cancer drug candidate arfolitixorin.
Other Board appointments
Board member of Baricol Bariatrics AB, Investmentaktiebolaget Akkumula AB and Albonja AB.
Other appointments
Anders is currently CEO of Mindforce Game Lab.
Holds 162 148 shares in Epicyt Pharma AB through Albonja AB
Martin is an Endocrinologist and Internal Medicine Specialist and holds a PhD from Lund University, Sweden, and an MBA from Copenhagen Business School, Denmark.
Martin has been Professor at Lund University Diabetes Center, Sweden, VP and Head of Clinic at Steno Diabetes Center, Denmark, CVP of Clinical Pharmacology and Translational Medicine at Novo Nordisk A/S, Denmark, and is currently SVP of Clinical Science at the Novo Nordisk Foundation, Denmark.
Other Board Appointments
Board member of the Steno Diabetes Center (SDC) Copenhagen, SDC Zeeland, SDC Odense, and SDC Greenland.
Holds 0 shares in Epicyt Pharma AB.
Ville is a Medical Doctor and PhD and holds a position as an Associate Professor at the Sahlgrenska Academy, University of Gothenburg and Consultant Surgeon at the Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.
Ville is a specialist in bariatric surgery and group leader of a research group conducting research on the mechanisms of action of bariatric surgery on metabolism as well as its adverse effects, e. g. on bone metabolism. He is together with Professor Lars Fändriks the inventor behind Epicyt Pharma AB
Other Board Appointments
Board member of the Swedish Society of Bariatric and Metabolic Surgery (Svensk Förening för Obesitas och metabol Kirurgi, SFOK) and board member of Dr Arnt Vestbys Research Foundation that appoints the yearly “Doctoral thesis of the Year” prize at the Sahlgrenska Academy at the University of Gothenburg. CEO of Villus Medical AB.
Holds 256 000 shares in Epicyt Pharma AB through Villus Medical AB.